Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Triple Negative Breast Neoplasms 2Carcinoma, Transitional Cell 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × eribulin × Clear all
NCT00337077 2014-06-23

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
121 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡